Variant | DSI v | DPI v | Chr | Position | Consequence | Alleles | Class | AF EXOME | AF GENOME | Disease | Disease Class | Score vda | EI vda | N. PMIDs | First Ref. | Last Ref. | ||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
1.000 | 0.040 | 9 | 22008805 | missense variant | G/A | snv | 4.5E-06 |
|
Neoplasms | 0.700 | 0 | ||||||||||
|
1.000 | 0.040 | 9 | 22006021 | missense variant | A/G | snv |
|
Neoplasms | 0.010 | 1.000 | 1 | 1997 | 1997 | ||||||||
|
1.000 | 0.080 | 9 | 22006096 | missense variant | C/G;T | snv | 4.2E-06; 8.4E-06 |
|
Neoplasms; Nervous System Diseases | 0.010 | 1.000 | 1 | 2001 | 2001 | |||||||
|
1.000 | 0.040 | 9 | 22008910 | missense variant | T/C | snv | 8.1E-06 |
|
Neoplasms | 0.010 | 1.000 | 1 | 2006 | 2006 | |||||||
|
1.000 | 0.040 | 9 | 22008910 | missense variant | T/C | snv | 8.1E-06 |
|
Neoplasms | 0.010 | 1.000 | 1 | 2006 | 2006 | |||||||
|
0.695 | 0.520 | 9 | 22003368 | 3 prime UTR variant | G/A;T | snv |
|
Neoplasms | 0.710 | 1.000 | 3 | 2009 | 2018 | ||||||||
|
0.695 | 0.520 | 9 | 22003368 | 3 prime UTR variant | G/A;T | snv |
|
Pathological Conditions, Signs and Symptoms; Cardiovascular Diseases | 0.010 | 1.000 | 1 | 2009 | 2009 | ||||||||
|
0.683 | 0.480 | 9 | 22003224 | 3 prime UTR variant | C/T | snv | 0.32 |
|
Pathological Conditions, Signs and Symptoms; Cardiovascular Diseases | 0.010 | 1.000 | 1 | 2009 | 2009 | |||||||
|
1.000 | 0.040 | 9 | 22005994 | missense variant | C/T | snv | 8.6E-06 |
|
Neoplasms | 0.010 | 1.000 | 1 | 2009 | 2009 | |||||||
|
1.000 | 0.040 | 9 | 22005994 | missense variant | C/T | snv | 8.6E-06 |
|
Neoplasms | 0.010 | 1.000 | 1 | 2009 | 2009 | |||||||
|
1.000 | 0.080 | 9 | 22010413 | intron variant | A/G | snv | 6.8E-02 |
|
Nutritional and Metabolic Diseases | 0.010 | 1.000 | 1 | 2010 | 2010 | |||||||
|
1.000 | 0.080 | 9 | 22010413 | intron variant | A/G | snv | 6.8E-02 |
|
Nutritional and Metabolic Diseases; Endocrine System Diseases | 0.010 | 1.000 | 1 | 2010 | 2010 | |||||||
|
0.695 | 0.520 | 9 | 22003368 | 3 prime UTR variant | G/A;T | snv |
|
Eye Diseases | 0.050 | 0.800 | 5 | 2011 | 2017 | ||||||||
|
0.695 | 0.520 | 9 | 22003368 | 3 prime UTR variant | G/A;T | snv |
|
Eye Diseases | 0.710 | 1.000 | 2 | 2011 | 2017 | ||||||||
|
0.925 | 0.040 | 9 | 22010005 | intron variant | T/A;G | snv |
|
Nutritional and Metabolic Diseases; Cardiovascular Diseases | 0.700 | 1.000 | 2 | 2011 | 2013 | ||||||||
|
0.683 | 0.480 | 9 | 22003224 | 3 prime UTR variant | C/T | snv | 0.32 |
|
Nutritional and Metabolic Diseases; Cardiovascular Diseases | 0.700 | 1.000 | 2 | 2011 | 2013 | |||||||
|
0.695 | 0.520 | 9 | 22003368 | 3 prime UTR variant | G/A;T | snv |
|
Neoplasms | 0.010 | 1.000 | 1 | 2011 | 2011 | ||||||||
|
0.695 | 0.520 | 9 | 22003368 | 3 prime UTR variant | G/A;T | snv |
|
Nutritional and Metabolic Diseases; Cardiovascular Diseases | 0.700 | 1.000 | 1 | 2011 | 2011 | ||||||||
|
0.695 | 0.520 | 9 | 22003368 | 3 prime UTR variant | G/A;T | snv |
|
Neoplasms | 0.010 | 1.000 | 1 | 2011 | 2011 | ||||||||
|
1.000 | 0.040 | 9 | 22009699 | intron variant | G/C | snv | 0.70 |
|
Nutritional and Metabolic Diseases; Cardiovascular Diseases | 0.700 | 1.000 | 1 | 2011 | 2011 | |||||||
|
1.000 | 0.040 | 9 | 22003791 | 3 prime UTR variant | T/C | snv | 7.3E-02 |
|
Cardiovascular Diseases | 0.010 | 1.000 | 1 | 2011 | 2011 | |||||||
|
0.683 | 0.480 | 9 | 22003224 | 3 prime UTR variant | C/T | snv | 0.32 |
|
Endocrine System Diseases | 0.010 | 1.000 | 1 | 2011 | 2011 | |||||||
|
0.683 | 0.480 | 9 | 22003224 | 3 prime UTR variant | C/T | snv | 0.32 |
|
Nutritional and Metabolic Diseases; Endocrine System Diseases | 0.010 | 1.000 | 1 | 2011 | 2011 | |||||||
|
0.683 | 0.480 | 9 | 22003224 | 3 prime UTR variant | C/T | snv | 0.32 |
|
Neoplasms | 0.700 | 1.000 | 1 | 2011 | 2011 | |||||||
|
0.695 | 0.520 | 9 | 22003368 | 3 prime UTR variant | G/A;T | snv |
|
Eye Diseases | 0.810 | 1.000 | 3 | 2012 | 2012 |